News FDA panel backs Ardelyx CKD drug, despite agency concerns While the FDA seems to remain sceptical about the clinical benefits of Ardelyx's chronic kidney disease (CKD) therapy Xphozah – having
News Hard times at Ardelyx as FDA rejects kidney disease drug ten... The FDA has taken a longer than usual look at Ardelyx's regulatory submission for tenapanor, a drug for high blood phosphate levels associated with chronic kidney disease (CKD), and found i
Views & Analysis Ardelyx’s ambition to revolutionise kidney treatment A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company Ardelyx.
News Parexel buys Vitrana to boost patient safety toolkit Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.